Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040 - Yau, T; Zagonel, V; Santoro, A (J Clin Oncol, 2020)